Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:
“This sentence is from a just-published paper on the efficacy of liposomal irinotecan in biliary tract cancer (BTC) in a very respectable journal.
In the words of my program director, Tim Moynihan, 20 years ago.
‘Patients do not fail therapy. The therapy fails the patient.’ “
Title: Real-world outcomes of fluorouracil-based second-line therapy in patients with advanced biliary tract cancer refractory to gemcitabine and cisplatin-based treatment
Authors: Se Jun Park, Kabsoo Shin, Hyunho Kim, Hyung Soon Park, Tae Ho Hong, In-Ho Kim, MyungAh Lee
You can read the Full Article in Therapeutic Advances in Medical Oncology.
More posts featuring Thor Halfdanarson.